Peptide therapy cost in 2026: the four routes, and what your money actually buys

Search “peptide therapy cost” and you’ll get a wall of numbers that don’t agree with each other — because “peptide therapy” isn’t one thing. It’s a marketing umbrella stretched over four very different transactions: a compounded telehealth prescription, a brand-name approved drug, a clinic injection program, and an unregulated powder mailed from a website that calls it “research material.” Each has its own price logic. Here is what they actually cost in 2026, and — the part the longevity copy skips — what your money is really buying.

Route 1 — Telehealth prescriptions: sermorelin is the workhorse

Strip away the longevity branding and the single most common “peptide therapy” a healthy adult is actually sold is compounded sermorelin — a growth-hormone-releasing hormone analog that nudges your pituitary to release its own growth hormone rather than injecting the hormone directly.^[1] It’s the workhorse of the telehealth peptide market for a simple reason: it has a genuine clinical pedigree, it’s cheap to compound, and it photographs well in a “recovery and vitality” ad.

As of mid-2026, the pricing clusters tightly. Yucca lists Personalized Sermorelin at $192 a month on its three-month plan. Eden advertises sermorelin from $126 for the first month, a typical “intro” rate that steps up on renewal. Across the major telehealth sellers the all-in monthly figure — medication, the clinician review, and shipping from the compounding pharmacy — lands in roughly the $120 to $300 a month band, with the spread driven mostly by plan length and whether a provider is dangling a first-order discount. None of these prices is touched by insurance, because compounded sermorelin for “wellness” isn’t a covered indication.

Route 2 — Brand-name approved peptide drugs: a different universe

A handful of peptides are FDA-approved drugs with a real label, and their pricing has nothing to do with the telehealth menu. The clearest example is tesamorelin, sold as Egrifta — itself a GHRH analog, but approved for a narrow medical indication: reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy.^[2] The pivotal program that earned that approval was a rigorous, randomized placebo-controlled trial — with a safety extension — showing real reductions in visceral adipose tissue,^[3] and a follow-on analysis confirmed that the visceral-fat reduction tracked with an improved metabolic profile.^[4]

Because Egrifta is a manufactured biologic produced for a small patient population — not a compounded wellness product — it sits in the high-cost specialty tier, the kind of drug whose list price runs into the thousands of dollars per month and is normally accessed through insurance and a manufacturer support program rather than paid cash. The FDA approval record and the current prescribing label spell out that this is a specific medical therapy, not a longevity supplement (Theratechnologies’ Egrifta label, DailyMed^[5]). The takeaway isn’t the exact sticker — it’s the category gap: an approved peptide biologic and a compounded telehealth vial of the closely related sermorelin are priced an order of magnitude apart, for reasons that have more to do with regulation and manufacturing than with how “advanced” the molecule is. For the clinical side of that story, see our tesamorelin (Egrifta) evidence review.

Route 3 — Clinic and med-spa programs: the widest variance

The third route is the in-person clinic or med-spa “peptide program” — and it carries the widest price variance of all, because the number on the invoice has the least to do with the peptide itself. You’re paying for the office visit, the in-clinic injection or a self-inject starter kit, often a panel of labs, and frequently an upsell into adjacent “optimization” services like vitamin or NAD+ IV drips. A single peptide protocol bundled with consults and labs can run from a few hundred dollars to well over a thousand for an onboarding package, with monthly maintenance layered on top.

Two cost drivers explain the spread. The first is the menu: clinics rarely sell one peptide; they sell stacks, and each addition (a BPC-157 course for recovery, a separate weight-management injectable) compounds the bill. The second is positioning — a concierge longevity clinic and a strip-mall med-spa can dispense the same compounded sermorelin at wildly different prices. Before paying a clinic premium, it’s worth checking how thin the evidence is for some of the popular add-ons; our BPC-157 evidence review is a useful reality check on one of the most-upsold “recovery” peptides.

Route 4 — The gray market: cheap sticker, unpriced risk

Search any peptide name and you’ll find sites selling it as a powder “for research use only, not for human consumption.” The per-vial price looks like a fraction of the telehealth route, and that gap is the entire pitch. But the disclaimer is doing real work: these products sit outside the prescription and compounding-pharmacy system, with no one verifying that the vial contains what the label says, at the stated dose, free of contaminants.

The best window into that risk comes from the adjacent, better-studied gray market for GLP-1 drugs. A 2024 market-surveillance study that actually purchased and laboratory-tested semaglutide products sold online without a prescription found a litany of problems — unregistered sellers, products that never arrived, and analyzed content that diverged from the label, including impurities and dose mismatches.^[6] Peptides bought the same way carry the same structural hazard: you are not buying a cheaper version of the regulated product, you are buying an unknown one. That reframes the “savings” entirely — a low sticker price attached to an unquantified risk isn’t cheap, it’s just unpriced. (To be explicit: this is a cost-versus-risk observation, not a recommendation to source peptides this way.)

How to spend wisely: anchor price to evidence

The honest organizing principle is this: most peptides marketed for longevity are biomarker stories, not outcome stories. They can move a lab value — IGF-1 rises with growth-hormone secretagogues, for instance^[7] — without there being large trials showing they extend healthspan, build meaningful muscle, or reverse aging in healthy adults. That distinction should drive the spend. Before committing to any monthly fee, it’s worth mapping the specific peptide against what the literature actually supports; our peptide evidence matrix grades each one so you aren’t paying outcome prices for biomarker evidence. And if your real goal is weight loss — a category where some peptides have genuine, large-trial backing — start with peptides for weight loss: the evidencerather than a generic “peptide therapy” package.

The honest bottom line

“Peptide therapy” costs whatever the route charges, and the routes are wildly different. The realistic figure for most healthy adults is compounded sermorelin at roughly $120–$300 a month through telehealth — a convenience fee for a cheap, legitimate molecule whose anti-aging case is still mostly biomarker-deep. Approved peptide drugs like tesamorelin live in a separate, specialty-biologic price tier for genuine medical indications. Clinic programs cost more and vary the most because you’re buying services and stacks, not a scarce drug. And the gray-market powder that looks cheapest is the one transaction where the price tag hides the real cost. The smart move isn’t to find the lowest number — it’s to anchor whatever you pay to the evidence. To compare the legitimate telehealth options on price and care model, see our peptide therapy provider comparison.